GlycoMimetics Inc (NASDAQ:GLYC)
| 3.39 Delayed Data As of Jan 27 |  0.00 / 0.00%Today’s Change | 0.51 Today|||52-Week Range 3.60 | +11.88% Year-to-Date |
Latest GLYC News | Press Releases
No recent news for GlycoMimetics Inc.
Today’s Trading
| Previous close | 3.39 |
| Today’s open | 3.50 |
| Day’s range | 3.21 - 3.59 |
| Volume | 34,951 |
| Average volume (3 months) | 576,013 |
| Market cap | $177.7M |
Data as of 3:59pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -10.46% |
| Earnings growth (this year) | +25.75% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -88.59% |
| P/E ratio | NM |
| Price/Sales | 63.89 |
| Price/Book | 2.17 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| OVIDOvid Therapeutics In... | 0.00 | 0.00% |
| DMTRF3-D Matrix Ltd | 0.00 | 0.00% |
| AFMDAffimed NV | 0.00 | 0.00% |
| CTMXCytomX Therapeutics ... | -0.01 | -0.36% |
Data as of 4:00pm ET, 01/27/2023
Financials
| Next reporting date | March 2, 2023 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $1.2M |
| Annual profit (last year) | -$63.4M |
| Net profit margin | -5,468.98% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Rockville, Maryland |
Forecasts
